- Stocks
- Pharma & Healthcare
- Supriya Lifescience
Supriya Lifescience share price
NSE: SUPRIYAPharma & HealthcareBiotechnology
Supriya Lifescience at a glance
Supriya Lifescience (NSE: SUPRIYA) closed at ₹848.80 on 22 Oct 2026, down 0.02% on the day. With a market capitalisation of ₹6,831 Cr, it ranks 670th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 32.7× trailing earnings, against a return on equity of 17.5% in FY26. Over the past year the share price has risen 19.4%. Its 52-week range is ₹545.50 (24 Mar 2026) to ₹1,085.00 (1 Jun 2026); the last close is 21.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹592 Cr (+15.6% year on year) and net profit −₹59 Cr, on a consolidated basis. Promoters held 68.30% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,831 CrRank 670 on NSE
- P/E (trailing)
- 32.7×
- Price to book
- 3.8×FY26
- EPS (TTM)
- ₹113.77to Q1 FY27
- ROE
- 17.5%FY26
- ROCE
- 22.4%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 25.3%FY26
- Book value / share
- ₹148.81FY26
- 52-week high
- ₹1,085.001 Jun 2026
- 52-week low
- ₹545.5024 Mar 2026
- 1-year return
- +19.4%
- RSI (14-day)
- 41.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.02% | −2.4% | −11.6% | +0.8% | +19.4% |
Supriya Lifescience quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹563 Cr | ₹529 Cr | ₹587 Cr | ₹512 Cr | ₹495 Cr | ₹501 Cr | ₹518 Cr | ₹592 Cr |
| Revenue YoY | +89.9% | −3.9% | +5.8% | −11.9% | −12.1% | −5.3% | −11.7% | +15.6% |
| Net profit | −₹54 Cr | −₹44 Cr | ₹143 Cr | −₹58 Cr | −₹65 Cr | −₹52 Cr | ₹426 Cr | −₹59 Cr |
| Net profit YoY | — | — | — | — | — | — | +197.1% | — |
| Net margin | −9.7% | −8.4% | 24.4% | −11.3% | −13.1% | −10.4% | 82.3% | −10.0% |
| EPS | −₹26.79 | −₹20.34 | ₹68.03 | −₹26.20 | −₹29.19 | −₹23.55 | ₹193.42 | −₹26.91 |
Supriya Lifescience financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹530 Cr | ₹461 Cr | ₹570 Cr | ₹696 Cr | — |
| Operating profit | ₹207 Cr | ₹123 Cr | ₹166 Cr | ₹248 Cr | — |
| Net profit | ₹152 Cr | ₹90 Cr | ₹119 Cr | ₹188 Cr | — |
| EPS (₹) | ₹18.86 | ₹11.16 | ₹14.80 | ₹23.35 | — |
| Cash from operations | ₹49 Cr | ₹66 Cr | ₹113 Cr | ₹165 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹616 Cr | ₹699 Cr | ₹815 Cr | ₹997 Cr | ₹1,198 Cr |
Supriya Lifescience shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| Foreign institutions | 7.19% | 6.78% | 5.46% | 5.20% | 5.16% | 6.19% |
| Domestic institutions | 4.26% | 4.86% | 5.22% | 5.01% | 5.70% | 5.30% |
| Non-institutions | 20.26% | 20.06% | 21.02% | 21.50% | 20.84% | 20.21% |
Supriya Lifescience vs peers
The listed Pharma & Healthcare companies nearest to Supriya Lifescience by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| THYROCAREThyrocare Technologies | ₹470.65 | +3.44% | +11.6% | ₹7,491 Cr | 46.2 | — |
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
| SANOFISanofi India | ₹2,845.00 | +0.53% | −40.0% | ₹6,552 Cr | 21.2 | — |
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
Ask anything about Supriya Lifescience
Pivot answers on the live chart with evidence you can check, and tests strategies against SUPRIYA's own history. Try: “Why has SUPRIYA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SUPRIYA over five years” · “Compare SUPRIYA with THYROCARE on margins and valuation”
Frequently asked questions about Supriya Lifescience
What is the share price of Supriya Lifescience today?
Supriya Lifescience (NSE: SUPRIYA) last closed at ₹848.80 on 22 Oct 2026. Its 52-week high is ₹1,085.00 and its 52-week low is ₹545.50.
What is the market cap of Supriya Lifescience?
Supriya Lifescience's market capitalisation is ₹6,831 Cr (₹6,831 Cr) at the 22 Oct 2026 close, ranking 670th among the NSE companies Pivot tracks.
What is the P/E ratio of Supriya Lifescience?
Supriya Lifescience trades at a trailing P/E of 32.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 53.1.
What is the ROE and ROCE of Supriya Lifescience?
Return on equity was 17.5% in FY26 and return on capital employed was 22.4% in FY26 (standalone figures).
Is Supriya Lifescience a debt-free company?
Supriya Lifescience is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Supriya Lifescience's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Supriya Lifescience reported revenue of ₹592 Cr, +15.6% year on year, and net profit of −₹59 Cr.
How has Supriya Lifescience stock performed over the last year?
Supriya Lifescience's share price has risen 19.4% over the past year, +0.8% over three months and −11.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Supriya Lifescience?
As of 30 Jun 2026: promoters 68.30%, foreign institutions 6.19%, domestic institutions 5.30%, non-institutions 20.21%.
Who are Supriya Lifescience's competitors?
The listed Pharma & Healthcare companies closest to Supriya Lifescience by market cap are Thyrocare Technologies, Morepen Laboratories, Bliss GVS Pharma, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.
Is Supriya Lifescience a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Supriya Lifescience's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUPRIYA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text